Vascular Closure Devices Market Size, Share, Growth, and Industry Analysis, By Type (Passive Approximators,Active Approximators), By Application (Interventional Cardiology,Interventional Radiology/Vascular Surgery), Regional Insights and Forecast to 2035

Vascular Closure Devices Market Overview

The global Vascular Closure Devices Market is forecast to expand from USD 1316.65 million in 2026 to USD 1403.95 million in 2027, and is expected to reach USD 2346.76 million by 2035, growing at a CAGR of 6.63% over the forecast period.

Global vascular closure devices (VCDs) are essential for achieving arterial hemostasis after catheterization. In 2024, the global market was estimated at USD 1.56 billion (Grand View) and USD 1.77 billion (Credence), reflecting differences in methodology but confirming strong growth. Active approximators accounted for about 65.7% of global device share in 2024, with some regional estimates showing passive approximators above 55%. Femoral access remains dominant, representing over 60% of all closures worldwide.

In the U.S., interventional cardiology is a key driver: more than 1.3 million cardiac catheterization procedures are performed annually, with >85% requiring closure devices for rapid patient mobilization. In 2024, the U.S. vascular closure devices segment was worth approximately USD 530 million (Precedence), representing 44.4% of North America’s market. The U.S. also leads globally in innovation, with over 20 FDA-cleared closure devices available across passive, active, and external hemostatic categories.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Active approximators represented 65.7% of global device usage in 2024.
• Major Market Restraint: Manual compression persists in up to 12% of cases due to safety concerns.
• Emerging Trends: External hemostatic devices expanded by 8–12% in newer hospital markets.
• Regional Leadership: North America captured a 44.4% share of global adoption in 2024.
• Competitive Landscape: Top 2 firms controlled 25–30% of the combined share in Western markets.
• Market Segmentation: Passive approximators 55%, active approximators 35%, and external hemostatic devices the balance.
• Recent Development: Between 2023–2024, five new devices expanded global portfolios by 15–20%.

Vascular Closure Devices Market Latest Trends

The vascular closure devices market is undergoing rapid modernization. Plug-based devices accounted for 40–50% of new shipments in 2024, overtaking sutures in some Western hospitals. External hemostatic device usage expanded from 8% in 2022 to ~11% in 2024 in Asia-Pacific region, reflecting demand for faster recovery in outpatient settings. Adoption of radial access closures grew from 12% in 2022 to 18% in 2024, driven by reduced complication rates and patient comfort. In Europe, bioabsorbable collagen plug use increased 20% in 2023, reducing residual material risks.

In the U.S., closure device use exceeded 85% of elective angioplasty cases by 2024. Procedure time was cut by 45–60% versus manual compression, improving hospital throughput. In emerging economies, China and India reported 25–30% annual growth in unit volumes during 2023–2024, fueled by over 700 combined new cath labs. Overall, minimally invasive procedures expanded 5–7% annually across developed countries, pushing closure device demand higher.

Vascular Closure Devices Market Dynamics

DRIVER

"Rising prevalence of cardiovascular and peripheral vascular interventions."

Rising cardiovascular intervention volumes: Over 20 million coronary procedures and 2.5 million peripheral vascular interventions occur annually. In the U.S., 1.3 million catheterizations drive demand, with hospitals reporting a 45% rise in device consumption between 2020–2024.

RESTRAINT

"Risks and complications in device use."

Device-related complications: Limb ischemia, infection, or device failures occur in 1.5–3% of procedures. Up to 12% of centers still prefer manual compression. Suture-based devices caused ~40% of adverse events logged in FDA databases.

OPPORTUNITY

"Growth in high-volume outpatient cath labs and ambulatory surgical centers."

Growth in outpatient centers: ASCs grew 20–25% between 2021–2024 in the U.S., adopting closure devices in >90% of procedures. India and China added 300–400 new labs annually during 2022–2024, each fueling new demand.

CHALLENGE

"Cost constraints and reimbursement variability in emerging regions."

Cost and reimbursement barriers: Device use in Latin America is limited to 20–30% of procedures due to affordability. In Africa, penetration is <10%. Import tariffs add 8–15% cost overhead, while regulatory delays stretch to 36 months in some countries.

Vascular Closure Devices Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Passive Approximators: Accounted for 55% of global share in 2024. In North America, they made up 50–60% of units. Collagen plugs alone cover 30–35% of passive use. Emerging markets prefer them in ~60% of new centers due to ease of training and complication rates as low as 0.8–1.5%.

The passive approximators segment is projected to generate USD 618.92 million in 2025, capturing 50.1% of the overall vascular closure devices market. This segment is expected to advance steadily at a CAGR of 6.40% from 2025 to 2034. Passive approximators remain popular due to their simpler deployment, reduced complications, and lower cost compared to active devices, which makes them particularly suitable in standard interventional cardiology cases. Hospitals and catheterization laboratories continue to adopt these solutions widely, especially in high-volume cardiovascular centers across the United States, Europe, and Asia, where standardized procedural care is expanding at a steady pace.

Top 5 Major Dominant Countries in the Passive Approximators Segment

• United States: The U.S. will lead this segment with USD 236.45 million in 2025, representing 38.2% of global passive approximators.
• Germany: Germany will contribute USD 72.80 million in 2025, accounting for 11.7% market share.
• Japan: Japan’s passive approximator market is expected at USD 61.95 million in 2025, representing a 10% share.
• China: China will record USD 57.34 million in 2025, covering 9.2% of the global passive segment.
• United Kingdom: The U.K. is forecasted to reach USD 42.67 million in 2025, capturing 6.9% share of the passive approximator market.

Active Approximators: Represent 35–40% of global share but 65.7% of U.S. sales. Suture-based systems dominate in complex or obese patients, used in up to 80% of large-bore access cases. Clip-based devices cover 5–8% of the active segment.

The active approximators segment is projected to achieve USD 615.86 million in 2025, accounting for 49.9% of the vascular closure devices market. With a forecasted CAGR of 6.85% from 2025 to 2034, this segment is expected to outpace passive approximators due to higher precision, reduced complications, and suitability for complex vascular procedures. Hospitals performing interventional radiology and advanced vascular surgeries increasingly prefer active devices, as they provide faster hemostasis and reduce hospital stay duration.

Top 5 Major Dominant Countries in the Active Approximators Segment

• United States: The U.S. will dominate this segment with USD 248.61 million in 2025, representing 40.4% of the global active approximators market.
• France: France is estimated to reach USD 69.25 million in 2025, holding 11.2% share of active approximators.
• India: India will account for USD 59.85 million in 2025, representing 9.7% of the active segment.
• China: China will capture USD 57.41 million in 2025, contributing 9.3% share of the segment. Expected growth at 6.80% CAGR is fueled by tertiary hospitals shifting towards active closure devices, an annual procedure count exceeding 800,000, and rising healthcare modernization investments.
• Italy: Italy’s active approximator market will record USD 43.92 million in 2025, accounting for 7.1% global share. Growth at 6.65% CAGR is supported by expansion of interventional cardiology programs, government-backed healthcare reforms, and steady growth in minimally invasive vascular procedures across private and public hospitals.

BY APPLICATION

Interventional Cardiology: Dominates with 60–65% of closures globally. In the U.S., ~85% of closures occur in PCI, stenting, and diagnostic angiography. Europe records ~58% cardiology share. Over 1.5 million coronary interventions annually require closure devices.

The interventional cardiology segment is projected to reach USD 802.61 million in 2025, accounting for 65% of the overall vascular closure devices market. With a forecasted CAGR of 6.60% during 2025–2034, this application dominates due to the rising prevalence of cardiovascular diseases and the increasing number of percutaneous coronary interventions (PCI) performed globally. More than 3 million PCI procedures are conducted worldwide annually, with vascular closure devices playing a critical role in ensuring patient safety and reducing recovery times.

Top 5 Major Dominant Countries in the Interventional Cardiology Application

• United States: The U.S. will lead this segment with USD 289.15 million in 2025, representing 36% of the global interventional cardiology share. Growing at 6.75% CAGR, demand is driven by more than 1.2 million PCI procedures annually and robust insurance coverage for cardiovascular interventions.
• China: China will contribute USD 97.92 million in 2025, holding 12.2% share of the segment. With a strong CAGR of 6.85%, growth is underpinned by more than 800,000 annual PCI procedures, rising incidence of coronary artery disease, and government investments in expanding cardiac care facilities.
• Germany: Germany is forecasted at USD 81.47 million in 2025, representing 10.1% of global interventional cardiology applications. Growing at 6.55% CAGR, the country benefits from over 400 active catheterization laboratories and a strong emphasis on adopting advanced closure devices.
• Japan: Japan will account for USD 75.62 million in 2025, covering 9.4% share of the application. Growth at 6.45% CAGR is driven by an aging population, rising cardiovascular disease prevalence, and more than 200,000 PCI procedures conducted annually across advanced urban hospitals.
• India: India is projected at USD 66.41 million in 2025, capturing 8.2% market share. The application is forecasted to expand at a 6.95% CAGR, supported by over 600,000 annual angioplasty procedures, rapid growth of private healthcare infrastructure, and increasing affordability of advanced vascular devices.

Interventional Radiology / Vascular Surgery: Holds 35–40% of demand. Peripheral procedures exceeded 2.5 million globally in 2023, with 45–50% requiring closure. Adoption in emerging economies grew 25% in 2023–2024, supported by dual-access kits.

The interventional radiology and vascular surgery segment is expected to achieve USD 432.17 million in 2025, representing 35% of the global vascular closure devices market. With a CAGR of 6.70% from 2025 to 2034, this application is expanding rapidly due to the shift toward minimally invasive vascular procedures and the growing preference for endovascular surgeries. These procedures, including aneurysm repair, thrombectomy, and peripheral interventions, increasingly utilize closure devices to ensure effective hemostasis and reduce hospital stays. Hospitals in developed countries are leading adoption, while emerging economies are quickly catching up as interventional radiology becomes a mainstream specialty in tertiary care centers.

Top 5 Major Dominant Countries in the Interventional Radiology/Vascular Surgery Application

• United States: The U.S. will dominate this segment with USD 180.21 million in 2025, representing 41.7% share of the application. Growing at 6.85% CAGR, demand is fueled by over 500,000 vascular surgery and radiology-based interventions annually, alongside rapid adoption of new-generation closure devices in academic centers.
• France: France is estimated at USD 49.84 million in 2025, covering 11.5% share of interventional radiology/vascular surgery. The segment is projected to grow at 6.65% CAGR, supported by leading teaching hospitals and a national trend toward minimally invasive vascular procedures.
• China: China’s share in this segment will reach USD 47.01 million in 2025, representing 10.9% of global demand. With a 6.90% CAGR, expansion is driven by rapid healthcare modernization, growth in interventional vascular programs, and more than 300,000 annual minimally invasive vascular surgeries.
• Italy: Italy will account for USD 39.87 million in 2025, representing 9.2% market share. Growth at 6.60% CAGR is attributed to strong cardiovascular and vascular surgery programs across public hospitals, with an increasing number of advanced interventional radiology procedures performed annually.
• Brazil: Brazil is projected at USD 36.29 million in 2025, holding 8.4% share of the segment. Expected to grow at 6.70% CAGR, this growth is fueled by more than 150,000 annual vascular interventions, expanding access to private healthcare, and rising preference for minimally invasive techniques.

Vascular Closure Devices Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America led with 44.4% global share in 2024. The U.S. accounted for USD 530 million in device usage, with >1.3 million catheterizations annually. Closure adoption exceeded 85% of elective cases across >5,000 hospitals and ASCs. Canada contributed 10–12% of regional demand, with adoption at ~70–75%. Over 10 new FDA approvals were granted between 2021–2024.

The North American vascular closure devices market is projected at USD 476.82 million in 2025, holding 38.6% of the global share. The region is expected to expand at a CAGR of 6.70% between 2025 and 2034, driven by high procedure volumes, advanced cardiovascular centers, and strong reimbursement policies. Over 1.5 million interventional cardiology and radiology procedures are conducted annually across the United States and Canada, making North America the single largest market for vascular closure devices.

North America - Major Dominant Countries in the Vascular Closure Devices Market

• United States: The U.S. will dominate with USD 417.12 million in 2025, representing 87.5% of the North American market. With a CAGR of 6.80%, growth is supported by more than 1.2 million angioplasties annually, advanced interventional radiology centers, and widespread use of vascular closure technologies.
• Canada: Canada will record USD 29.37 million in 2025, capturing 6.2% of the regional share. The market will expand at 6.55% CAGR, supported by modernized cardiac catheterization labs, more than 100,000 cardiovascular interventions annually, and rapid integration of closure devices into national care standards.
• Mexico: Mexico is estimated at USD 18.44 million in 2025, covering 3.9% of North America. Growing at 6.45% CAGR, demand is driven by increasing adoption of minimally invasive procedures and government investment in public hospitals performing over 50,000 cardiac interventions annually.
• Cuba: Cuba will contribute USD 6.84 million in 2025, representing 1.4% share of the regional market. With a CAGR of 6.35%, growth is modest but sustained due to gradual expansion of cardiovascular care facilities and reliance on imported closure devices.
• Costa Rica: Costa Rica is forecasted at USD 5.05 million in 2025, accounting for 1% regional share. Expected to grow at 6.30% CAGR, demand is supported by expanding private hospital networks and rising numbers of interventional radiology procedures across tertiary centers.

EUROPE

Europe contributed 25–30% of global use in 2024. Germany reported ~70% adoption in PCI cases, France ~60–65%, and the U.K. ~55% by 2024. Eastern Europe lagged at 30–40% but rising. Plug-based passive devices held 45% share in Western Europe, while bioabsorbable plugs grew 20% in Italy and Spain. Peripheral usage increased from 30% to 38% in 2024.

The European vascular closure devices market will reach USD 364.94 million in 2025, representing 29.6% of the global share. Growth at 6.55% CAGR is supported by the continent’s advanced healthcare systems, strong cardiovascular research base, and widespread adoption of minimally invasive vascular procedures. Europe accounts for nearly 1 million annual PCI procedures, making vascular closure devices critical for patient recovery and efficiency. Countries such as Germany, France, and the United Kingdom dominate, driven by both public healthcare investments and the presence of global device manufacturers in the region.

Europe - Major Dominant Countries in the Vascular Closure Devices Market

• Germany: Germany will lead Europe with USD 92.35 million in 2025, accounting for 25.3% of the regional market. With 6.45% CAGR, growth is supported by more than 400 catheterization laboratories, rising vascular interventions, and strong preference for advanced closure devices.
• France: France will record USD 74.18 million in 2025, representing 20.3% regional share. At 6.60% CAGR, the market benefits from strong interventional radiology adoption, leading cardiac surgery centers, and more than 250,000 annual vascular procedures.
• United Kingdom: The U.K. is forecasted at USD 64.24 million in 2025, covering 17.6% share. Growing at 6.55% CAGR, the country benefits from NHS investments, with over 250,000 interventional cardiology and radiology cases annually adopting closure devices.
• Italy: Italy will reach USD 59.15 million in 2025, capturing 16.2% share of Europe. With a CAGR of 6.50%, demand is driven by cardiovascular procedure volumes exceeding 200,000 annually and expanded adoption of active approximators in hospitals.
• Spain: Spain is projected at USD 53.02 million in 2025, accounting for 14.5% regional share. Growth at 6.40% CAGR is supported by more than 180,000 annual interventional procedures and strong integration of closure devices into national cardiology protocols

ASIA-PACIFIC

Asia-Pacific accounted for 15–20% of global use in 2024. China’s >3,000 cath labs achieved 60% closure adoption, with >30% annual growth 2022–2024. India added 300–400 new labs annually, averaging 50% adoption. Japan used closure devices in 75% of cases; South Korea in 68%. Southeast Asia adoption remained ~25–35% but growing 20–25% yearly.

The Asian vascular closure devices market will be USD 288.24 million in 2025, representing 23.3% of the global market. The region is expected to grow at 6.80% CAGR, making it the fastest-growing market globally due to expanding healthcare infrastructure, a large patient base, and rising cardiovascular disease prevalence. Asia performs over 2 million cardiovascular interventions annually, with China, Japan, and India driving more than 80% of regional demand. Rapid adoption of advanced interventional procedures in tier-1 hospitals and government-led healthcare reforms are further boosting device penetration.

Asia - Major Dominant Countries in the Vascular Closure Devices Market

• China: China will dominate with USD 122.15 million in 2025, representing 42.4% of Asia. With a CAGR of 6.85%, growth is supported by more than 800,000 annual PCI procedures, government expansion of tertiary hospitals, and rising use of advanced closure technologies.
• Japan: Japan is projected at USD 85.33 million in 2025, accounting for 29.6% of the Asian share. Growth at 6.70% CAGR is fueled by an aging population, over 200,000 annual interventions, and widespread use of closure devices in leading hospitals.
• India: India will account for USD 61.45 million in 2025, holding 21.3% share. The market will expand at 6.95% CAGR, driven by more than 600,000 angioplasties annually, increasing hospital expansions, and a growing preference for active approximators.
• South Korea: South Korea will record USD 10.26 million in 2025, representing 3.6% of Asia. With a CAGR of 6.60%, demand is driven by a rising number of interventional radiology procedures and strong healthcare infrastructure in Seoul and major cities.
• Singapore: Singapore is forecasted at USD 9.05 million in 2025, covering 3.1% share. Growing at 6.55% CAGR, adoption is supported by highly developed hospitals, government-backed healthcare innovation, and strong uptake of closure devices in vascular surgeries.

MIDDLE EAST & AFRICA

MEA contributed <10% of global share in 2024. GCC hospitals like UAE and Saudi Arabia achieved 50–60% adoption, while South Africa reached ~40%. Nigeria and Kenya remained below 10%. Regional device suppliers added 100–150 new hospital accounts in 2023–2024. Price cuts of 8–12% via tariff reductions improved uptake in Egypt and Morocco.

The Middle East and Africa vascular closure devices market is forecasted at USD 104.78 million in 2025, representing 8.5% of the global share. The region is expected to expand at a CAGR of 6.50% during 2025–2034, driven by rapid adoption of interventional cardiology and radiology procedures. With over 300,000 annual cardiovascular interventions across the region, demand is concentrated in countries such as Saudi Arabia, the United Arab Emirates, and South Africa, where advanced hospitals are investing heavily in modern closure technologies.

Middle East and Africa - Major Dominant Countries in the Vascular Closure Devices Market

• Saudi Arabia: Saudi Arabia will dominate with USD 31.42 million in 2025, capturing 30% of the regional market. With a CAGR of 6.55%, growth is driven by hospital expansions, the rising prevalence of cardiovascular diseases, and government investments in specialized cardiac centers.
• United Arab Emirates: The UAE is projected at USD 26.74 million in 2025, accounting for 25.5% of the region. Growing at 6.60% CAGR, demand is supported by world-class hospitals in Dubai and Abu Dhabi and rising demand for minimally invasive procedures.
• South Africa: South Africa will record USD 22.59 million in 2025, representing 21.6% share. With a CAGR of 6.45%, adoption is fueled by over 100,000 annual interventional procedures and the modernization of major hospitals across Johannesburg and Cape Town.
• Egypt: Egypt is forecasted at USD 15.71 million in 2025, holding 15% of the regional share. Growing at 6.40% CAGR, demand is supported by public healthcare investments and expanding adoption of interventional radiology in government-run hospitals.
• Nigeria: Nigeria will achieve USD 8.32 million in 2025, representing 8% share of the market. Expected to grow at 6.35% CAGR, demand is driven by population growth, rising heart disease burden, and the gradual introduction of modern closure technologies in private hospitals.

List of Top Vascular Closure Devices Companies

• Cardinal Health
• Vivasure Medical
• Vascular Closure Systems
• Morrris Innovative
• Essential Medical
• Abbott Laboratories
• Jude Medical
• Medeon Biodesign
• Transluminal Technologies
• Vasorum
• Beijing Puyishengji Medical Technology
• InSeal Medical
• Arstasis
• Vascular Solutions

Top Two Companies with Highest Share:

Abbott Laboratories: Holds ~10–12% share in U.S. and Europe, driven by product depth in plug-based devices.

Cardinal Health: Accounts for ~8–10% share with extensive distribution networks and hospital contracts.

Investment Analysis and Opportunities

Between 2022–2024, >USD 50 million in venture funding was raised across eight deals for closure startups. Top firms increased R&D spending by 12%. U.S. ASC growth of 20–25% created new investment demand, while three distributor acquisitions occurred in Europe in 2023–2024. In Asia, an Indian OEM raised USD 10 million in 2023 to manufacture domestic closure systems. The Middle East VC sector invested USD 5–8 million into vascular medtech. Bioresorbable plugs and polymer sealants attracted ~30% of innovation capital. Hospitals budgeted for 5–10 device additions annually, creating predictable channels for investors.

New Product Development

From 2023–2025, eight new devices were approved worldwide. A U.S. collagen-gel plug with pressure feedback cut bleeding events by 20% in 12 pilot hospitals. Europe introduced a polymeric sealant in 2023 with 15 lab adoptions, absorbing in 30 days. Asia received a low-cost device in 2024, with >1,000 placements in six months. A dual-access kit was piloted in 10 U.S. centers in 2025. A clip-based approximator reduced hemostasis time by 30%. Patents rose by 15 in 2023, covering polymers, anchors, and smart feedback.

Five Recent Developments

• 2023 – Smart collagen plug launched in U.S., 5,000+ units placed.
• 2024 – Polymeric sealant system adopted by 15 European labs.
• 2024 – Low-cost closure device released in India & China, 1,000+ units sold.
• 2024 – Dual-access kit trialed in 10 U.S. centers with 200 kits each.
• 2025 – Clip-based approximator reduced hemostasis time by 30% in 50 cases.

Report Coverage of Vascular Closure Devices Market

This report covers device type (passive, active, external hemostatic), access route (femoral, radial), application (cardiology, radiology, vascular surgery), and end user (hospitals, ASCs). Regional coverage spans North America, Europe, Asia-Pacific, and MEA. It includes adoption rates, pricing, reimbursement, and regulatory frameworks across 30+ countries. Patent landscaping shows 15+ filings in 2023. Competitive benchmarking highlights that top 2 companies hold 15–18% share combined. Emerging trends include smart sensors, bioresorbable materials, and dual-access kits. Forecast models extend to 2032, examining unit growth, product launches, and M&A activity.

Vascular Closure Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1316.65 Million in 2026
Market Size Value By	USD 2346.76 Million by 2035
Growth Rate	CAGR of 6.63% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Passive Approximators Active Approximators By Application : Interventional Cardiology Interventional Radiology/Vascular Surgery
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample